EMPLOYMENT AGREEMENTEmployment Agreement • September 10th, 2020 • C4 Therapeutics, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Employment Agreement (“Agreement”) is made by and between C4 Therapeutics (the “Company”), and (the “Executive”), and is effective as of this __ day of __________, 20__ (the “Effective Date”).
C4 THERAPEUTICS, INC. [FORM OF] DIRECTOR INDEMNIFICATION AGREEMENTDirector Indemnification Agreement • September 10th, 2020 • C4 Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
This Indemnification Agreement (“Agreement”) is made as of [Date] by and between C4 Therapeutics, Inc., a Delaware corporation (the “Company”), and [Director Name] (“Indemnitee”).
C4 THERAPEUTICS, INC. [FORM OF] OFFICER INDEMNIFICATION AGREEMENTOfficer Indemnification Agreement • September 10th, 2020 • C4 Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
This Indemnification Agreement (“Agreement”) is made as of [Date] by and between C4 Therapeutics, Inc., a Delaware corporation (the “Company”), and [Officer Name] (“Indemnitee”). 1
LEASE BY 480 ARSENAL GROUP LLC, LANDLORD TO C4 THERAPEUTICS, INC., TENANT LINX Building 490 Arsenal Way Watertown, Massachusetts 02472Lease • September 10th, 2020 • C4 Therapeutics, Inc. • Biological products, (no disgnostic substances) • Massachusetts
COLLABORATION AND LICENSE AGREEMENTCollaboration and License Agreement • September 10th, 2020 • C4 Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
This Collaboration and License Agreement (“Agreement”) is entered into with effect as of March 13, 2017 (the “Effective Date”) by and between C4 Therapeutics, Inc. with an office and place of business at 675 W. Kendall St., Cambridge, MA 02142 (“C4T”) and Calico Life Sciences LLC with an office and place of business at 1170 Veterans Blvd, South San Francisco, CA 94080 (“Calico”) (a “Party” or together, “Parties”).
Amended and Restated License AgreementLicense Agreement • September 10th, 2020 • C4 Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
with an office and place of business at 150 Clove Road, Suite 8, Little Falls, New Jersey 07424, U.S.A. (“Roche US”; Roche Basel and Roche US together referred to as “Roche”)
COLLABORATIVE RESEARCH AND LICENSE AGREEMENT BETWEEN BIOGEN MA INC. AND C4 THERAPEUTICS, INC. Dated December 28, 2018Collaborative Research and License Agreement • September 10th, 2020 • C4 Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
This COLLABORATIVE RESEARCH AND LICENSE AGREEMENT (this “Agreement”) is entered into as of December 28, 2018 (the “Effective Date”) by and among Biogen MA Inc., a corporation organized and existing under the laws of Massachusetts and having a principal place of business at 225 Binney Street, Cambridge, MA 02142 (“Biogen”) and C4 Therapeutics, Inc., a corporation organized and existing under the laws of Delaware with a principle place of business at 490 Arsenal Way, Watertown, MA 02472 (“C4”). Biogen and C4 are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF...Credit Agreement • September 10th, 2020 • C4 Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
CREDIT AGREEMENT AND GUARANTY, dated as of June 5, 2020 (this “Agreement”), among C4 THERAPEUTICS, INC., a Delaware corporation (the “Borrower”), certain Guarantors from time to time parties hereto, PERCEPTIVE CREDIT HOLDINGS III, LP, a Delaware limited partnership (“Perceptive”), as a lender (together with its successors and assigns party hereto pursuant to Section 13.05, the “Lenders” and each a “Lender”) and as administrative agent for the Lenders (in such capacity, together with its successors and assigns, the “Administrative Agent”).
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • September 10th, 2020 • C4 Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of June 5, 2020, by and among C4 Therapeutics, Inc., a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor”, the stockholders set forth on Schedule B hereto as the “Key Holders”, and any additional purchaser that becomes a party to this Agreement in accordance with Section 6.9 hereof (collectively, the “Additional Purchasers”).
C4 THERAPEUTICS, INC. CONSULTATION AGREEMENTConsultation Agreement • September 10th, 2020 • C4 Therapeutics, Inc. • Biological products, (no disgnostic substances) • Massachusetts
Consultation Agreement (“Agreement”), effective as of March 31, 2020 (the “Effective Date”), between C4 Therapeutics, Inc., a Delaware corporation, having a place of business at 490 Arsenal Way, Suite 200, Watertown, MA 02472 (“C4T” or “Company”), and MBJC Associates, LLC having an address at 832 Schirra Drive, Oradell, New Jersey 07649 (“Consultant”).
